HomeQuestion

How do you manage refractory myelofibrosis with thrombocytopenia, significant leukocytosis (>150), and ASXL1 mutation?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Do you recommend GLP-1 agonists in patients with MPN?

Do you forego aspirin use in essential thrombocythemia if they are already on clopidogrel?

For low/intermediate essential thrombocythemia not on cytoreduction, would you temporarily cytoreduce in anticipation of surgery?

How do you manage the side effects of ropeginterferon alfa 2b for polycythemia vera patients?

Do you routinely stop ESA when starting myelofibrosis patients on JAK inhibitor therapy?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.